Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin …
C Wysham, RC Bonadonna, VR Aroda… - Diabetes, Obesity …, 2017 - Wiley Online Library
Aims To assess the impact of baseline characteristics on clinical outcomes in the LixiLan‐L
trial, a randomized open‐label trial designed to evaluate the efficacy and safety of iGlarLixi …
trial, a randomized open‐label trial designed to evaluate the efficacy and safety of iGlarLixi …
Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination …
To determine whether baseline characteristics had an impact on clinical outcomes in the
LixiLan‐O trial (N= 1170), we compared the efficacy and safety of iGlarLixi, a titratable fixed …
LixiLan‐O trial (N= 1170), we compared the efficacy and safety of iGlarLixi, a titratable fixed …
How effective is the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) in different patient populations, and when should it be used in clinical practice …
J Tibaldi, ME Mercado, J Strong - Clinical Diabetes, 2020 - Am Diabetes Assoc
The efficacy and safety of the fixed-ratio combination of insulin degludec (degludec) and
liraglutide (IDegLira) were confirmed in the DUAL clinical trial program, in which IDegLira …
liraglutide (IDegLira) were confirmed in the DUAL clinical trial program, in which IDegLira …
[PDF][PDF] Сахарный диабет
MD Ampudia-Blasco, MD Christine Yu… - Diabetes Obes …, 2017 - logospress.ru
При анализе подгрупп, независимо от исходного уровня HbA1c, длительности
заболевания и ИМТ, применение Соликвы неизменно приводило к улучшению …
заболевания и ИМТ, применение Соликвы неизменно приводило к улучшению …
When and how to Use A Glp-1 ra With Long-or Ultralong-Acting Basal Insulin in T2Dm
B Bode - Endocrine Practice, 2016 - endocrinepractice.org
In the United States, there are 8 major drug classes available for the management of
hyperglycemia—basal insulin, prandial insulin, sulfonylureas, biguanides …
hyperglycemia—basal insulin, prandial insulin, sulfonylureas, biguanides …
When and how to Use Ultralong-Acting Basal Insulin in T2Dm
AJ Garber - Endocrine Practice, 2016 - endocrinepractice.org
Recent advances in insulin pharmacology, metallurgy, and insulin delivery technology have
largely remediated the difficulties associated with insulin injection circa 1925. Each …
largely remediated the difficulties associated with insulin injection circa 1925. Each …
The History of Insulin Technology: A Brief Review of the Updates in Basal Insulin Therapy Through the Years
AJ Garber - Endocrine Practice, 2016 - endocrinepractice.org
DPP-4= dipeptidyl peptidase-4; eGFR= estimated glomerular filtration rate; EPY=
events/person-year; FDA= Food and Drug Administration; FPG= fasting plasma glucose; …
events/person-year; FDA= Food and Drug Administration; FPG= fasting plasma glucose; …
When and how to Use Prandial Insulin with Ultralong-Acting Basal Insulin in T2Dm
GE Umpierrez - Endocrine Practice, 2016 - endocrinepractice.org
Two ultralong-acting basal insulins were approved for use in the United States in 2015: U-
300 glargine is a concentrated formulation of the more familiar U-100 glargine, and …
300 glargine is a concentrated formulation of the more familiar U-100 glargine, and …